Breath test could spot dangerous lung clots
NCT ID NCT07241130
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether measuring carbon dioxide in a person's breath (called end-tidal CO₂) can help doctors quickly identify severe blood clots in the lungs and see if treatment is working. Researchers studied 120 adults, including those with different levels of clot severity and healthy volunteers. The goal was to see if this simple, noninvasive test could replace more complex procedures for guiding emergency care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
120 people
The number who actually took part.
- Started
-
Feb 2025
- Finished
-
Jul 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
This study included adult patients diagnosed with acute pulmonary embolism who were classified as high-risk or intermediate-high-risk based on hemodynamic status, right ventricular dysfunction, and cardiac biomarker elevation. Participants were consecutively enrolled at a tertiary university medical center. The study also included a healthy control group composed of adults without cardiopulmonary disease or significant medical comorbidities. A total of 120 individuals were studied across four cohorts representing different clinical risk categories and routine treatment pathways.
- Ages
-
18 to 80 years
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Adults aged 18 years or older Diagnosis of acute pulmonary embolism confirmed by CT pulmonary angiography (for PE groups) Classified as high-risk or intermediate-high-risk pulmonary embolism according to ESC/ERS 2019 guidelines Ability to provide informed consent For healthy control group: no history of cardiopulmonary disease, coagulation disorders, or acute medical illness Exclusion Criteria: Known chronic respiratory diseases significantly affecting EtCO₂ measurement (e.g., advanced COPD, severe asthma, chronic respiratory failure) Active infection, sepsis, or acute complications of malignancy Prior thrombolytic therapy for pulmonary embolism Anatomical or technical limitations preventing reliable nasal capnography Pregnancy Individuals younger than 18 years Inability or refusal to provide informed consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pulmonary embolism acute are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ataturk University
Erzurum, 25200, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can half the Clot-Busting drug save lives with less bleeding?
- AI plus ultrasound could catch heart and lung decline before it turns critical
- Can a Clot-Removing device ease acute pulmonary embolism?
- Can a catheter device clear lung clots and ease heart strain?
- Which blood thinner is safer for lung clots? a Head-to-Head test
- Can a simple electrical scan spot dangerous lung clots without radiation?